Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages 1033-1042

  Scholtysik, René ^a   Kreuz, Markus ^b   Hummel, Michael ^c   Rosolowski, Maciej ^b   Szczepanowski, Monika ^d   Klapper, Wolfram ^d   Loeffler, Markus ^b   Trümper, Lorenz ^e   Siebert, Reiner ^f   Küppers, Ralf ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Diffuse large B cell lymphoma; Genomic imbalances; Tumor suppressor gene

Indexed keywords

ADULT; ARTICLE; BACH2 GENE; CASP3 GENE; CASP8AP2 GENE; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GERM CELL TUMOR; GERMINAL CENTER; HDAC7A GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IL5RA GENE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOGENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; COHORT ANALYSIS; DNA MICROARRAY; FEMALE; GENETICS; GENOMICS; MALE; PROGNOSIS; TUMOR RECURRENCE;

COHORT STUDIES; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84918800993     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29072     Document Type: Article

References (51)

1. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29.
2. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
3. Seifert M, Scholtysik R, Küppers R. Origin and pathogenesis of B cell lymphomas. Methods Mol Biol 2013;971:1-25.
4. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012;22:359-72.
5. Green MR, Aya-Bonilla C, Gandhi MK, et al. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 2011;50:313-26.
6. Scandurra M, Mian M, Greiner TC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol 2010;151:221-31.
7. Takeyama K, Monti S, Manis JP, et al. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large Bcell lymphomas. Oncogene 2008;27:318-22.
8. Swerdlow SH, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: International Agency for Research on Cancer, 2008.
9. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using highdensity oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-9.
10. Lin M, Wei LJ, Sellers WR, et al. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-40.
11. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007;104:20007-12.
12. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-6.
13. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.
14. Beroukhim R, Lin M, Park Y, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2006;2:e41.
15. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004;36:949-51.
16. Pollard KS, Ge Y, Dudoit S. Multtest: resamplingbased multiple hypothesis testing, R package version 1.12.0, 2006. Available at: http://CRAN. Rproject.org/package?multtest. Accessed on October 18, 2010.
17. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
18. Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011;118:139-47.
19. Scholtysik R, Nagel I, Kreuz M, et al. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. Int J Cancer 2012;131:E830-E835.
20. Jardin F, Jais JP, Molina TJ, et al. Diffuse large Bcell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010;116:1092-104.
21. Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476-87.
22. Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010;18:580-9.
23. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
24. Oudejans JJ, Van Wieringen WN, Smeets SJ, et al. Identification of genes putatively involved in the pathogenesis of diffuse large B-cell lymphomas by integrative genomics. Genes Chromosomes Cancer 2009;48:250-60.
25. Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large Bcell lymphoma using whole-genome sequencing. Blood 2013;122:1256-65.
26. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-5.
27. Fukuhara N, Tagawa H, Kameoka Y, et al. Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. Cancer Sci 2006;97:499-504.
28. Sakane-Ishikawa E, Nakatsuka S, Tomita Y, et al. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J Clin Oncol 2005;23:8012-17.
29. Milovic-Holm K, Krieghoff E, Jensen K, et al. FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. EMBO J 2007;26:391-401.
30. Mian M, Scandurra M, Chigrinova E, et al. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol 2012;23:729-35.
31. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-62.
32. Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92:3018-24.
33. Ochiai K, Muto A, Tanaka H, et al. Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol 2008;20:453-60.
34. Kojima Y, Tsurumi H, Goto N, et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol 2006;76:465-72.
35. Hangaishi A, Kurokawa M. Blimp-1 is a tumor suppressor gene in lymphoid malignancies. Int J Hematol 2010;91:46-53.
36. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-17.
37. Kim HD, Kim TS, Kim J. Aberrant ribosome biogenesis activates c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest. Oncogene 2011;30:3317-27.
38. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008;13:1215-22.
39. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large Bcell lymphoma. Blood 2010;116:3268-77.
40. Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747-52.
41. Zhu C, Chen Q, Xie Z, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl) 2011;89:279-89.
42. Lemercier C, Brocard MP, Puvion-Dutilleul F, et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2002;277:22045-52.
43. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-95.
44. Witzig TE, Price-Troska TL, Stenson MJ, et al. Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained. Leuk Lymphoma 2013;54:397-9.
45. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
46. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 2008;414:13-21.
47. Provencio M, Martin P, Garcia V, et al. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010;51:2021-30.
48. Takatsu K, Kouro T, Nagai Y. Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol 2009;101:191-236.
49. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011;476:163-9.
50. Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012;119:1882-7.
51. Scholtysik R, Kreuz M, Klapper W, et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica 2010;95:2047-55.